A novel nomenclature for repeat motifs in the thymidylate synthase enhancer region and its relevance for pharmacogenetic studies

Dominic Schaerer, Tanja K. Froehlich, Seid Hamzic, Steven M. Offer, Robert B. Diasio, Markus Joerger, Ursula Amstutz, Carlo R. Largiadèr

Research output: Contribution to journalArticlepeer-review

Abstract

Inhibition of thymidylate synthase (TS) is the primary mode of action for 5-fluorouracil (5FU) chemotherapy. TS expression is modulated by a variable number of tandem repeats in the TS enhancer region (TSER) located upstream of the TS gene (TYMS). Variability in the TSER has been suggested to contribute to 5FU-induced adverse events. However, the precise genetic associations remain largely undefined due to high polymorphism and ambiguity in defining genotypes. To assess toxicity associations, we sequenced the TSER in 629 cancer patients treated with 5FU. Of the 13 alleles identified, few could be unambiguously named using current TSER-nomenclature. We devised a concise and unambiguous systematic naming approach for TSER-alleles that encompasses all known variants. After applying this comprehensive naming system to our data, we demonstrated that the number of upstream stimulatory factor (USF1-)binding sites in the TSER was significantly associated with gastrointestinal toxicity in 5FU treatment.

Original languageEnglish (US)
Article number181
Pages (from-to)1-13
Number of pages13
JournalJournal of Personalized Medicine
Volume10
Issue number4
DOIs
StatePublished - Dec 2020

Keywords

  • 5-fluorouracil
  • Adverse drug reactions
  • Capecitabine
  • Fluoropyrimidine
  • Thymidylate synthase
  • Thymidylate synthase enhancer region
  • Upstream stimulatory factor 1

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'A novel nomenclature for repeat motifs in the thymidylate synthase enhancer region and its relevance for pharmacogenetic studies'. Together they form a unique fingerprint.

Cite this